WO2000020638A9 - Methods and compositions for the diagnosis and therapy of prostate cancer - Google Patents
Methods and compositions for the diagnosis and therapy of prostate cancerInfo
- Publication number
- WO2000020638A9 WO2000020638A9 PCT/US1999/022575 US9922575W WO0020638A9 WO 2000020638 A9 WO2000020638 A9 WO 2000020638A9 US 9922575 W US9922575 W US 9922575W WO 0020638 A9 WO0020638 A9 WO 0020638A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tspy
- prostate cancer
- prostate
- mrna
- protein
- Prior art date
Links
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 85
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 77
- 238000000034 method Methods 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 238000002560 therapeutic procedure Methods 0.000 title abstract description 11
- 238000003745 diagnosis Methods 0.000 title abstract description 9
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 22
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 22
- 239000002157 polynucleotide Substances 0.000 claims abstract description 22
- 230000014509 gene expression Effects 0.000 claims description 46
- 210000001519 tissue Anatomy 0.000 claims description 41
- 108020004999 messenger RNA Proteins 0.000 claims description 32
- 210000002307 prostate Anatomy 0.000 claims description 29
- 101000845189 Homo sapiens Testis-specific Y-encoded protein 1 Proteins 0.000 claims description 26
- 230000002163 immunogen Effects 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 238000013518 transcription Methods 0.000 claims description 11
- 230000035897 transcription Effects 0.000 claims description 11
- 230000000692 anti-sense effect Effects 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 238000013519 translation Methods 0.000 claims description 9
- 102000045506 human TSPY1 Human genes 0.000 claims description 8
- 102000053642 Catalytic RNA Human genes 0.000 claims description 7
- 108090000994 Catalytic RNA Proteins 0.000 claims description 7
- 108091092562 ribozyme Proteins 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 210000000988 bone and bone Anatomy 0.000 claims description 6
- 108091026890 Coding region Proteins 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 2
- 102100031283 Testis-specific Y-encoded protein 1 Human genes 0.000 claims 17
- 230000000295 complement effect Effects 0.000 claims 2
- 230000001926 lymphatic effect Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 102
- 102000004169 proteins and genes Human genes 0.000 abstract description 60
- 239000012634 fragment Substances 0.000 abstract description 22
- 102100030072 Doublesex- and mab-3-related transcription factor 3 Human genes 0.000 abstract description 5
- 101000797917 Homo sapiens 1,5-anhydro-D-fructose reductase Proteins 0.000 abstract description 5
- 101000864825 Homo sapiens Doublesex- and mab-3-related transcription factor 3 Proteins 0.000 abstract description 5
- 102000054584 human Y acceptor Human genes 0.000 abstract description 3
- 108700023876 human Y acceptor Proteins 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 53
- 206010028980 Neoplasm Diseases 0.000 description 42
- 230000001225 therapeutic effect Effects 0.000 description 35
- 239000002299 complementary DNA Substances 0.000 description 26
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 22
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 201000010099 disease Diseases 0.000 description 20
- 201000011510 cancer Diseases 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 238000010240 RT-PCR analysis Methods 0.000 description 18
- 239000000523 sample Substances 0.000 description 18
- 238000013459 approach Methods 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 15
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 14
- 238000003556 assay Methods 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 239000003098 androgen Substances 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 108020004635 Complementary DNA Proteins 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 101710120463 Prostate stem cell antigen Proteins 0.000 description 7
- 210000004443 dendritic cell Anatomy 0.000 description 7
- 238000010195 expression analysis Methods 0.000 description 7
- 210000001550 testis Anatomy 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 6
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 6
- 208000023958 prostate neoplasm Diseases 0.000 description 6
- 102100032187 Androgen receptor Human genes 0.000 description 5
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 5
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 5
- 108010080146 androgen receptors Proteins 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 5
- 229940030749 prostate cancer vaccine Drugs 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 108091060211 Expressed sequence tag Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- -1 SISBA Proteins 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 230000001582 osteoblastic effect Effects 0.000 description 3
- 201000007094 prostatitis Diseases 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 206010027452 Metastases to bone Diseases 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 206010071019 Prostatic dysplasia Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 238000010317 ablation therapy Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 208000035392 hereditary 6 prostate cancer Diseases 0.000 description 2
- 208000032154 hereditary 8 prostate cancer Diseases 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000035346 Margins of Excision Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101150102573 PCR1 gene Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000004965 Prostatic Intraepithelial Neoplasia Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010054184 Small intestine carcinoma Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 108700021042 biotin binding protein Proteins 0.000 description 1
- 102000043871 biotin binding protein Human genes 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000002937 blood-testis barrier Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000002701 cell growth assay Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229940124452 immunizing agent Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000000010 osteolytic effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 208000021046 prostate intraepithelial neoplasia Diseases 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000000722 protumoral effect Effects 0.000 description 1
- 238000011472 radical prostatectomy Methods 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000010323 transrectal needle biopsy Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/342—Prostate diseases, e.g. BPH, prostatitis
Definitions
- the invention described herein relates to methods and compositions for the diagnosis and therapy of prostate cancer utilizing isolated polynucleotides, polypeptides, antibodies, and related molecules which correspond to or are reactive with human
- Prostate cancer is the most frequently diagnosed cancer and second leading cause of cancer death in men. Some 45,000 men die annually of this disease. Only lung cancer has a higher mortality. The chance of a man developing invasive prostate cancer during his lifetime is 1 in 6. At the age of 50, a man has a greater than 40% chance of developing prostate cancer and nearly a 3% chance of dying from this disease. While some advances in the treatment of locally confined tumors have been achieved, prostate cancer is incurable once it has metastasized. Patients with metastatic prostate cancer are treated by hormonal ablation therapy, but with only short-term success. Eventually, these patients develop an androgen-refractory state leading to disease progression and death.
- a continuing and fundamental problem in the management of prostate cancer is the absence of reliable diagnostic and prognostic markers capable of accurately detecting early-stage localized tumors and/or predicting disease susceptibility and progression.
- Early detection and diagnosis of prostate cancer currently relies on digital rectal examination (DRE), prostate specific antigen (PSA) measurements, transrectal ultrasonography (TRUS), and transrectal needle biopsy (TRNB).
- DRE digital rectal examination
- PSA prostate specific antigen
- TRUS transrectal ultrasonography
- TRNB transrectal needle biopsy
- Serum PSA measurements in combination with DRE represent the leading diagnostic approach at present.
- this approach has major limitations which have fueled intensive research into finding better diagnostic markers of this disease.
- a number of markers have been identified, and at least one, PSA, is in widespread clinical use.
- ideal prostate tumor markers have been extremely elusive and no marker has yet proven reliable for predicting progression of the disease.
- prostate-specific proteins that could be appropriate as therapeutic targets, as there is no effective treatment for patients who develop recurrent disease or who have been diagnosed with metastatic disease. Although hormone ablation therapy can palliate these patients, the majority inevitably progress to develop incurable, androgen-independent disease (Lalani et al., 1997, Cancer Metastasis Rev. 16: 29-66).
- PSA is the most widely used tumor marker for screening, diagnosis, and monitoring prostate cancer today.
- several immunoassays for the detection of serum PSA are in widespread clinical use.
- RT-PCR reverse transcriptase- polymerase chain reaction
- PSA is not a disease-specific marker, as elevated levels of PSA are detectable in a large percentage of patients with BPH and prostatitis (25- 86%)(Gao et al., 1997, Prostate 31 : 264-281 ), as well as in other nonmalignant disorders and in some normal men, a factor which significantly limits the diagnostic specificity of this marker.
- PSA diagnostics have sensitivities of between 57-79% (Cupp & Osterling, 1993, Mayo Clin Proc 68:297-306), and thus miss identifying prostate cancer in a significant population of men with the disease.
- PSMA Prostate-Specific Membrane Antigen
- PSMA expression is largely restricted to prostate tissues, but detectable levels of PSMA mRNA have been observed in brain, salivary gland, small intestine, and renal cell carcinoma (Israeli et al., 1993, Cancer Res 53: 227-230).
- PSMA protein is highly expressed in most primary and metastatic prostate cancers, but is also expressed in most normal intraepithelial neoplasia specimens (Gao et al., supra).
- PSMA is a hormone dependent antigen requiring the presence of functional androgen receptor. Since not all prostate cancer cells express androgen receptor, the clinical utility of PSMA as a therapeutic target may be inherently limited. Clinical trials designed to examine the effectiveness of PSMA immunotherapy are also underway.
- PSCA Prostate Stem Cell Antigen
- PIN prostatic intraepithelial neoplasia
- PIN prostatic intraepithelial neoplasia
- the PSCA gene has been mapped to chromosome 8q24.2, a region of allelic gain in more than 80% of prostate cancers.
- PSCA shows promise as a diagnostic and therapeutic target in view of its cell surface location, prostate specificity, and greatly upregulated expression in prostate cancer cells.
- DU-145 and PC-3 cell lines have been shown to reproducibly give rise to osteoblastic lesions typical of prostate cancer.
- a further limitation of the DU-145 and PC-3 cell lines is that these cells do not express prostate specific antigen (PSA) or androgen receptor (AR) (Kaighn et al., 1979, Invest. Urol. 17: 16-23; Gleave et al., 1992, Cancer Res. 52: 1598-1605), questioning their relevance to clinical prostate cancer.
- PSA prostate specific antigen
- AR androgen receptor
- the LNCaP cell line is androgen responsive and expresses PSA, but contains a mutation in the androgen receptor which alters ligand specificity.
- LAPC Long et al., 1997, Nature Med. 3: 402
- LAPC-4 Long et al., 1997, supra
- LAPC-4 tumors regress in male mice after castration, but re-grow within 2-3 months as androgen independent tumors.
- LAPC-4 xenograft tumors express equal levels of the prostate specific markers PSA, PSMA (prostate specific membrane antigen) and PSCA (prostate stem cell antigen), which was identified using representational difference analysis of cDNAs derived from the AD and Al variants of the LAPC-4 xenograft.
- PSA prostate specific markers
- PSMA prostate specific membrane antigen
- PSCA prostate stem cell antigen
- the present invention relates to methods and compositions for the diagnosis and therapy of prostate cancer.
- the methods of the invention utilize isolated polynucleotides corresponding to the human Y-specific gene TSPY (testis-specific protein Y-encoded) (Arnemann, J et al., 1991 , Genomics 11 : 108-114), proteins encoded by the TSPY gene and fragments thereof, and antibodies capable of specifically recognizing and binding to TSPY proteins.
- TSPY TSPY gene expression in normal human tissues is largely restricted to testis as determined by RT-PCR analyses. Substantially lower expression is detected in prostate only after very high PCR amplification cycles. RT-PCR analysis also demonstrates that the TSPY gene is variably over-expressed in prostate cancer xenografts relative to normal prostate. The biochemical and functional characteristics of TSPY have yet to be defined. Nevertheless, the expression profile of TSPY disclosed herein suggests that TSPY may be a useful diagnostic marker and/or therapeutic target for prostate cancer. In view of its testis specific expression in normal tissues, TSPY may in particular represent an excellent target for prostate cancer vaccines and immunotherapeutics.
- FIG. 1 Nucleotide (A) and amino acid (B) sequences of human TSPY (Arnemann, J et al., 1991 , Genomics 11 : 108-114). Bold nucleotide sequence corresponds initially isolated SSH-derived fragment of the TSPY gene.
- FIG. 2 Nucleotide sequence of the initially isolated SSH-derived fragment of the TSPY gene.
- FIG. 3 RT-PCR analysis of TSPY gene expression in prostate cancer xenografts, normal prostate, and other tissues and cell lines, showing high level over-expression in the LAPC-4 AD and Al prostate cancer xenografts, and lower level over-expression in the LAPC-9 AD xenograft, relative to normal prostate (Panel A); and showing expression only in testis in normal tissues at 30 cycles of PCR amplification, and lower level expression in prostate only after 35 cycles (Panels B and C).
- FIG. 4 Northern blot showing testis-specific TSPY expression in normal tissues (Panels A and B) and up-regulated expression in prostate cancer (Panel C).
- the present invention relates to methods and compositions for the diagnosis and therapy of prostate cancer which utilize isolated polynucleotides corresponding to the human Y-specific gene TSPY (testis-specific protein Y-encoded) (Arnemann, J et al., 1991 , Genomics 11 : 108-114), proteins encoded by the TSPY gene and fragments thereof, and antibodies capable of specifically recognizing and binding to TSPY proteins.
- TSPY is a recently described gene which encodes a predicted 308 amino acid protein. The physiological role of TSPY is unknown.
- the invention is based, in part, upon the isolation of a cDNA fragment corresponding to the TSPY gene by Suppression Subtraction Hybridization cloning.
- This cDNA designated 31 P1A2
- the 31 P1A2 cDNA showed identity to the extreme 3' end of the untranslated sequence of the TSPY gene.
- Primers designed to specifically amplify the gene corresponding to 31 P1 A2 were then used to characterize TSPY expression in prostate cancer xenografts, normal prostate, and a variety of other normal tissues.
- the nucleotide and amino acid sequences of TSPY are provided in FIG.1
- the nucleotide sequence of the 31 P1A2 cDNA, corresponding to and identifying the TSPY gene is provided in FIG. 2.
- TSPY The expression profile of TSPY suggests that it may represent an ideal diagnostic and therapeutic marker for prostate cancer. As determined by both Northern blot and RT- PCR expression analysis, the expression of TSPY in normal tissues is highly restricted to testis (FIGS. 3 and 4). Very low level expression is detectable by RT-PCR in prostate (FIG. 3). Further, expression analysis of TSPY expression in prostate cancer xenografts (by both Northern blot and RT-PCR) indicates that this gene is over-expressed in prostate cancers, and at very high levels in some cases (FIG. 3, Panel A).
- the terms "advanced prostate cancer”, “locally advanced prostate cancer”, “advanced disease” and “locally advanced disease” mean prostate cancers which have extended through the prostate capsule, and are meant to include stage C disease under the American Urological Association (AUA) system, stage C1 - C2 disease under the Whitmore-Jewett system, and stage T3 - T4 and N+ disease under the TNM (tumor, node, metastasis) system.
- AUA American Urological Association
- stage C1 - C2 disease under the Whitmore-Jewett system
- TNM tumor, node, metastasis
- Locally advanced disease is clinically identified by palpable evidence of induration beyond the lateral border of the prostate, or asymmetry or induration above the prostate base.
- Locally advanced prostate cancer is presently diagnosed pathologically following radical prostatectomy if the tumor invades or penetrates the prostatic capsule, extends into the surgical margin, or invades the seminal vesicles.
- metastatic prostate cancer and “metastatic disease” mean prostate cancers which have spread to regional lymph nodes or to distant sites, and are meant to include stage D disease under the AUA system and stage TxNxM+ under the TNM system.
- surgery is generally not indicated for patients with metastatic disease, and hormonal (androgen ablation) therapy is the preferred treatment modality.
- Patients with metastatic prostate cancer eventually develop an androgen-refractory state within 12 to 18 months of treatment initiation, and approximately half of these patients die within 6 months thereafter.
- the most common site for prostate cancer metastasis is bone.
- Prostate cancer bone metastases are, on balance, characteristically osteoblastic rather than osteolytic (i.e., resulting in net bone formation).
- polynucleotide means a polymeric form of nucleotides of at least 10 bases or base pairs in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide, and is meant to include single and double stranded forms of DNA.
- polypeptide means a polymer of at least 10 amino acids. Throughout the specification, standard three letter or single letter designations for amino acids are used.
- hybridize As used herein, the terms “hybridize”, “hybridizing”, “hybridizes” and the like, used in the context of polynucleotides, are meant to refer to conventional hybridization conditions, preferably such as hybridization in 50% formamide/6XSSC/0.1% SDS/100 ⁇ g/ml ssDNA, in which temperatures for hybridization are above 37 degrees C and temperatures for washing in 0.1XSSC/0.1% SDS are above 55 degrees C, and most preferably to stringent hybridization conditions.
- identity is used to express the percentage of amino acid residues at the same relative position which are the same.
- homology is used to express the percentage of amino acid residues at the same relative positions which are either identical or are similar, using the conserved amino acid criteria of BLAST analysis, as is generally understood in the art. Further details regarding amino acid substitutions, which are considered conservative under such criteria, are provided below.
- TSPY gene may correlate with and identify prostate cancer and disease progression. Determining the status of TSPY expression patterns in an individual may be used to diagnose cancer and may provide prognostic information useful in defining appropriate therapeutic options. Similarly, the expression status of TSPY may provide information useful for predicting susceptibility to particular disease stages, progression, and/or tumor aggressiveness. Accordingly, the invention provides assays for detecting and monitoring prostate cancer by identifying and quantifying over- expression of TSPY in prostate cells.
- TSPY expression status in patient samples may be analyzed by a number of means well known in the art, including without limitation, immunohistochemical analysis, in situ hybridization, RT-PCR analysis on laser capture micro-dissected samples, western blot analysis of clinical samples and cell lines, and tissue array analysis.
- the invention provides assays useful in determining the presence of cancer in an individual, comprising detecting a significant increase in TSPY mRNA or protein expression in a test cell or tissue sample relative to expression levels in the corresponding normal cell or tissue.
- the presence of TSPY mRNA may, for example, be evaluated in tissue samples including but not limited to prostate, seminal vessicles, bone, serum, semen and lymphatic tissues.
- the presence of significant TSPY expression in any of these tissues may be useful to indicate the emergence, presence and/or severity of prostate cancer.
- TSPY expression status may be determined at the protein level rather than at the nucleic acid level.
- a method or assay would comprise determining the level of TSPY protein expressed by cells in a test tissue sample and comparing the level so determined to the level of TSPY expressed in a corresponding normal sample.
- the presence of TSPY protein is evaluated, for example, using immunohistochemical methods.
- TSPY antibodies or binding partners capable of detecting TSPY protein expression may be used in a variety of assay formats well known in the art for this purpose.
- tissue samples may be from prostate, seminal vessicles, semen, serum, bone and lymphatic tissues.
- peripheral blood may be conveniently assayed for the presence of prostate cancer cells using RT-PCR to detect TSPY expression.
- RT-PCR detection assays for tumor cells in peripheral blood are currently being evaluated for use in the diagnosis and management of a number of human solid tumors. In the prostate cancer field, these include RT-PCR assays for the detection of cells expressing PSA and PSM (Verkaik et al., 1997, Urol. Res. 25: 373-384; Ghossein et al., 1995, J. Clin. Oncol. 13: 1195-2000; Heston et al., 1995, Clin. Chem. 41 : 1687-1688). RT-PCR assays are well known in the art.
- a related aspect of the invention is directed to predicting susceptibility to developing prostate cancer in an individual.
- a method for predicting susceptibility to prostate cancer comprises detecting TSPY mRNA or TSPY protein in a prostate, bone, seminal vessicle or lymph tissue sample, or in serum or semen, its presence indicating susceptibility to prostate cancer, wherein the degree of TSPY mRNA expression present is proportional to the degree of susceptibility.
- the presence of TSPY in prostate tissue is examined, with the presence of TSPY in the sample providing an indication of prostate cancer susceptibility (or the emergence or existence of a prostate tumor).
- a method for gauging aggressiveness of a prostate tumor comprises determining the level of TSPY mRNA or TSPY protein expressed by cells in a sample of the tumor, comparing the level so determined to the level of TSPY mRNA or TSPY protein expressed in a corresponding normal tissue taken from the same individual or a normal tissue reference sample, wherein the degree of TSPY mRNA or TSPY protein expression in the tumor sample relative to the normal sample indicates the degree of aggressiveness.
- TSPY mRNA or protein Methods for detecting and quantifying the expression of TSPY mRNA or protein are described herein and use standard nucleic acid and protein detection and quantification technologies well known in the art.
- Standard methods for the detection and quantification of TSPY mRNA include in situ hybridization using labeled TSPY riboprobes, Northern blot and related techniques using TSPY polynucleotide probes, RT-PCR analysis using primers specific for TSPY, and other amplification type detection methods, such as, for example, branched DNA, SISBA, TMA and the like.
- semi-quantitative RT-PCR may be used to detect and quantify TSPY mRNA expression as described in the Examples which follow.
- any number of primers capable of amplifying TSPY may be used for this purpose, including but not limited to the various primer sets specifically described herein. Standard methods for the detection and quantification of protein may be used for this purpose.
- polyclonal or monoclonal antibodies specifically reactive with the wild-type TSPY protein may be used in an immunohistochemical assay of biopsied tissue.
- TSPY as a normally testis-specific protein that is highly expressed in cancers of the prostate opens a number of therapeutic approaches to the treatment of prostate cancers. Accordingly, therapeutic approaches aimed at inhibiting the activity of the TSPY protein are expected to be useful for patients suffering from prostate cancer. These therapeutic approaches generally fall into three classes.
- One class comprises various methods for inhibiting the binding or association of the TSPY protein with its binding partner or with others proteins.
- Another class comprises a variety of methods for inhibiting the transcription of the TSPY gene or translation of TSPY mRNA.
- a further class comprises various prostate cancer vaccine therapy strategies. A.
- recombinant vectors encoding single chain antibodies which specifically bind to TSPY may be introduced into TSPY expressing cells via gene transfer technologies, wherein the encoded single chain anti-TSPY antibody is expressed intracellularly, binds to TSPY protein, and thereby inhibits its function.
- Methods for engineering such intracellular single chain antibodies are well known.
- intracellular antibodies also known as "intrabodies” may be specifically targeted to a particular compartment within the cell, providing control over where the inhibitory activity of the treatment will be focused. This technology has been successfully applied in the art (for review, see Richardson and Marasco, 1995, TIBTECH vol. 13).
- Intrabodies have been shown to virtually eliminate the expression of otherwise abundant cell surface receptors. See, for example, Richardson et al., 1995, Proc. Natl. Acad. Sci. USA 92: 3137-3141 ; Beerli et al., 1994, J. Biol. Chem. 289: 23931-23936; Deshane et al., 1994, Gene Ther. 1 : 332-337.
- Single chain antibodies comprise the variable domains of the heavy and light chain joined by a flexible linker polypeptide, and are expressed as a single polypeptide.
- single chain antibodies may be expressed as a single chain variable region fragment joined to the light chain constant region.
- Well known intracellular trafficking signals may be engineered into recombinant polynucleotide vectors encoding such single chain antibodies in order to precisely target the expressed intrabody to the desired intracellular compartment.
- intrabodies targeted to the endoplasmic reticulum (ER) may be engineered to incorporate a leader peptide and, optionally, a C-terminal ER retention signal, such as the KDEL amino acid motif.
- Intrabodies intended to exert activity in the nucleus may be engineered to include a nuclear localization signal. Lipid moieties may be joined to intrabodies in order to tether the intrabody to the cytosolic side of the plasma membrane. Intrabodies may also be targeted to exert function in the cytosol. For example, cytosolic intrabodies may be used to sequester factors within the cytosol, thereby preventing them from being transported to their natural cellular destination.
- the transcription of the intrabody may be placed under the regulatory control of an appropriate prostate-specific promoter and/or enhancer, such as the PSA promoter and/or promoter/enhancer may be utilized (See, for example, U.S. Patent No. 5,919,652).
- an appropriate prostate-specific promoter and/or enhancer such as the PSA promoter and/or promoter/enhancer may be utilized (See, for example, U.S. Patent No. 5,919,652).
- the invention provides various methods and compositions for inhibiting the transcription of the TSPY gene.
- the invention also provides methods and compositions for inhibiting the translation of TSPY mRNA into protein.
- a method of inhibiting the transcription of the TSPY gene comprises contacting the TSPY gene with a TSPY antisense polynucleotide.
- a method of inhibiting TSPY mRNA translation comprises contacting the TSPY mRNA with an antisense polynucleotide.
- a TSPY specific ribozyme may be used to cleave the TSPY message, thereby inhibiting translation.
- Such antisense and ribozyme based methods may also be directed to the regulatory regions of the TSPY gene, such as the TSPY promoter and/or enhancer elements.
- proteins capable of inhibiting a TSPY gene transcription factor may be used to inhibit TSPY mRNA transcription.
- the various polynucleotides and compositions useful in the aforementioned methods have been described above. The use of antisense and ribozyme molecules to inhibit transcription and translation is well known in the art.
- TSPY PROSTATE CANCER VACCINES The invention further provides prostate cancer vaccines comprising a TSPY protein or fragment thereof, as well as DNA based vaccines.
- TSPY cancer vaccines are expected to be effective at specifically preventing and/or treating TSPY expressing cancers without creating non-specific effects on non-target tissues.
- the use of a tumor antigen in a vaccine for generating humoral and cell- mediated immunity for use in anti-cancer therapy is well known in the art and has been employed in prostate cancer using human PSMA and rodent PAP immunogens (Hodge et al., 1995, Int. J.
- TSPY protein or fragment thereof, or a TSPY-encoding nucleic acid molecule and recombinant vectors capable of expressing and appropriately presenting the TSPY immunogen.
- viral gene delivery systems may be used to deliver a TSPY-encoding nucleic acid molecule.
- Various viral gene delivery systems which can be used in the practice of this aspect of the invention include, but are not limited to, vaccinia, fowlpox, canarypox, adenovirus, influenza, poliovirus, adeno-associated virus, lentivirus, and Sindbus virus (Restifo, 1996, Curr. Opin. Immunol. 8: 658-663).
- Non-viral delivery systems may also be employed by using naked DNA encoding a TSPY protein or fragment thereof introduced into the patient (e.g., intramuscularly) to induce an anti- tumor response.
- the full-length human TSPY cDNA may be employed.
- TSPY nucleic acid molecules encoding specific cytotoxic T lymphocyte (CTL) epitopes may be employed.
- CTL epitopes can be determined using specific algorithms (e.g., Epimer, Brown University) to identify peptides within a TSPY protein which are capable of optimally binding to specified HLA alleles.
- Dendritic cells express MHC class I and II, B7 costimulator, and IL-12, and are thus highly specialized antigen presenting cells.
- PSMA prostate-specific membrane antigen
- Dendritic cells can be used to present TSPY peptides to T cells in the context of MHC class I and II molecules.
- autologous dendritic cells are pulsed with TSPY peptides capable of binding to MHC molecules.
- dendritic cells are pulsed with the complete TSPY protein.
- Yet another embodiment involves engineering the overexpression of the TSPY gene in dendritic cells using various implementing vectors known in the art, such as adenovirus (Arthur et al., 1997, Cancer Gene Ther. 4: 17-25), retrovirus (Henderson et al., 1996, Cancer Res.
- TSPY may also be engineered to express immune modulators, such as GM-CSF, and used as immunizing agents.
- Anti-idiotypic anti-TSPY antibodies can also be used in anti-cancer therapy as a vaccine for inducing an immune response to cells expressing a TSPY protein.
- the generation of anti-idiotypic antibodies is well known in the art and can readily be adapted to generate anti-idiotypic anti-TSPY antibodies that mimic an epitope on a TSPY protein (see, for example, Wagner et al., 1997, Hybridoma 16: 33-40; Foon et al., 1995, J Clin Invest 96: 334-342; Herlyn et al., 1996, Cancer Immunol Immunother 43: 65-76).
- Such an anti-idiotypic antibody can be used in cancer vaccine strategies.
- TSPY tumor necrosis virus
- Constructs comprising DNA encoding a TSPY protein/immunogen and appropriate regulatory sequences may be injected directly into muscle or skin of an individual, such that the cells of the muscle or skin take-up the construct and express the encoded TSPY protein/immunogen.
- Expression of the TSPY protein immunogen results in the generation of prophylactic or therapeutic humoral and cellular immunity against prostate cancer.
- Various prophylactic and therapeutic genetic immunization techniques known in the art may be used (for review, see information and references published at Internet address www.genweb.com).
- Gene transfer and gene therapy technologies may be used for delivering therapeutic polynucleotide molecules to tumor cells synthesizing TSPY (i.e., antisense, ribozyme, polynucleotides encoding intrabodies and other TSPY inhibitory molecules).
- TSPY i.e., antisense, ribozyme, polynucleotides encoding intrabodies and other TSPY inhibitory molecules.
- a number of gene therapy approaches are known in the art.
- Recombinant vectors encoding TSPY antisense polynucleotides, ribozymes, factors capable of interfering with TSPY transcription, and so forth, may be delivered to target tumor cells using such gene therapy approaches.
- the above therapeutic approaches may be combined with chemotherapy or radiation therapy regimens. These therapeutic approaches may also enable the use of reduced dosages of chemotherapy and/or less frequent administration, particularly in patients that do not tolerate the toxicity of the chemotherapeutic agent well.
- the anti-tumor activity of a particular composition may be evaluated using various in vitro and in vivo assay systems.
- In vitro assays for evaluating therapeutic potential include cell growth assays, soft agar assays and other assays indicative of tumor promoting activity, binding assays capable of determining the extent to which a therapeutic composition will inhibit the binding of TSPY to a binding partner, etc.
- a TSPY therapeutic composition may be evaluated in a suitable animal model.
- xenogenic prostate cancer models wherein human prostate cancer explants or passaged xenograft tissues are introduced into immune compromised animals, such as nude or SCID mice, are appropriate in relation to prostate cancer and have been described (Klein et al., 1997, Nature Medicine 3: 402- 408).
- PCT Patent Application W098/16628, Sawyers et al., published April 23, 1998 describes various xenograft models of human prostate cancer capable of recapitulating the development of primary tumors, micrometastasis, and the formation of osteoblastic metastases characteristic of late stage disease.
- xenografts from bearing mice treated with the therapeutic composition may be examined for the presence of apoptotic foci and compared to un-treated control xenograft-bearing mice. The extent to which apoptotic foci are found in the tumors of the treated mice provides an indication of the therapeutic efficacy of the composition.
- compositions used in the practice of the foregoing methods may be formulated into pharmaceutical compositions comprising a carrier suitable for the desired delivery method.
- Suitable carriers include any material which when combined with the therapeutic composition retains the anti-tumor function of the therapeutic composition and is non-reactive with the patient's immune system. Examples include, but are not limited to, any of a number of standard pharmaceutical carriers such as sterile phosphate buffered saline solutions, bacteriostatic water, and the like (see, generally, Remington's Pharmaceutical Sciences 16 th Edition, A. Osal., Ed., 1980).
- Therapeutic formulations may be solubilized and administered via any route capable of delivering the therapeutic composition to the tumor site.
- Potentially effective routes of administration include, but are not limited to, intravenous, parenteral, intraperitoneal, intramuscular, intratumor, intradermal, intraorgan, orthotopic, and the like.
- a preferred formulation for intravenous injection comprises the therapeutic composition in a solution of preserved bacteriostatic water, sterile unpreserved water, and/or diluted in polyvinylchloride or polyethylene bags containing 0.9% sterile Sodium Chloride for Injection, USP.
- Therapeutic protein preparations may be lyophilized and stored as sterile powders, preferably under vacuum, and then reconstituted in bacteriostatic water containing, for example, benzyl alcohol preservative, or in sterile water prior to injection.
- kits are also provided by the invention.
- Such kits may comprise a carrier means being compartmentalized to receive in close confinement one or more container means such as vials, tubes, and the like, each of the container means comprising one of the separate elements to be used in the method.
- one of the container means may comprise a probe which is or can be detectably labeled.
- probe may be an antibody or polynucleotide specific for a TSPY protein or a TSPY gene or message, respectively.
- the kit may also have containers containing nucleotide(s) for amplification of the target nucleic acid sequence and/or a container comprising a reporter-means, such as a biotin-binding protein, such as avidin or streptavidin, bound to a reporter molecule, such as an enzymatic, florescent, or radioisotope label.
- a reporter-means such as a biotin-binding protein, such as avidin or streptavidin
- TSPY COMPOSITIONS USED IN THE PRACTICE OF THE INVENTION For polynucleotide based detection of TSPY, various polynucleotides based on the structure of the TSPY cDNA provided herein are employed (FIG. 1). Standard molecular cloning, manipulation and synthesis technologies may be used to generate these compositions. TSPY polynucleotides useful in this aspect of the invention may comprise all or part of the cDNA provided herein (FIG. 1), or probes and primers designed to hybridize or amplify the TSPY message in a sample.
- Antisense molecules can be RNAs or other molecules, including peptide nucleic acids (PNAs) or non-nucleic acid molecules such as phosphorothioate derivatives, that specifically bind DNA or RNA in a base pair-dependent manner.
- PNAs peptide nucleic acids
- non-nucleic acid molecules such as phosphorothioate derivatives
- Probes may be labeled with a detectable marker, such as, for example, a radioisotope, fluorescent compound, bioluminescent compound, a chemiluminescent compound, metal chelator or enzyme.
- a detectable marker such as, for example, a radioisotope, fluorescent compound, bioluminescent compound, a chemiluminescent compound, metal chelator or enzyme.
- Such probes and primers can be used to detect the presence of a TSPY polynucleotide in a sample and as a means for detecting a cell expressing a TSPY protein.
- Examples of such probes include polypeptides comprising all or part of the human TSPY cDNA sequence shown in FIG. 1. Examples of primer pairs capable of specifically amplifying TSPY mRNAs are also described in the Examples which follow.
- a great many different primers and probes may be prepared based on the sequences provided in herein and used effectively to amplify and/or detect a TSPY
- TSPY proteins and polypeptides are useful in the practice of the prostate cancer vaccine therapies described herein as well as for the generation of antibodies specific for TSPY.
- Such TSPY proteins and polypeptides may be produced by a number of means well known in the art, including recombinant expression technologies and peptide systhesis methods.
- TSPY polypeptides containing particularly interesting structures can be predicted and/or identified using various analytical techniques well known in the art, including, for example, the methods of Chou-Fasman, Garnier-Robson, Kyte-Doolittle, Eisenberg, Karplus-Schultz or Jameson-Wolf analysis, or on the basis of immunogenicity. Fragments containing such structures are particularly useful in generating subunit specific anti-TSPY antibodies or in identifying cellular factors that bind to TSPY.
- Host-vector systems comprising a recombinant DNA molecule containing all or part of the TSPY coding sequence within a suitable prokaryotic or eukaryotic host cell may be used to express recombinant TSPY or polypeptides corresponding to part of TSPY.
- a wide range of host-vector systems suitable for the expression of TSPY proteins or fragments thereof are available, see for example, Sambrook et al., 1989, supra; Current Protocols in Molecular Biology, 1995, supra).
- suitable eukaryotic host cells include a yeast cell, a plant cell, or an animal cell, such as a mammalian cell or an insect cell (e.g., a baculovirus-infectible cell such as an Sf9 or HighFive cell).
- suitable mammalian cells include various prostate cancer cell lines such LnCaP, PC-3, DU145, LAPC-4, TsuP , other transfectable or transducible prostate cancer cell lines, as well as a number of mammalian cells routinely used for the expression of recombinant proteins (e.g., COS, CHO, 293, 293T cells).
- TSPY may be conveniently expressed in 293T cells transfected with a CMV-driven expression vector encoding TSPY with a C-terminal 6XHis and MYC tag (pcDNA3.1/mycHIS, Invitrogen).
- the secreted HIS-tagged TSPY in the culture media may then be purified using a nickel column using standard techniques.
- Other preferred vectors for mammalian expression include but are not limited to pcDNA 3.1 myc-His-tag (Invitrogen) and the retroviral vector pSR ⁇ tkneo (Muller et al., 1991 , MCB 11 :1785).
- Expression constructs encoding a leader peptide joined in frame to the TSPY coding sequence may be used for the generation of a secreted form of recombinant TSPY protein.
- Antibodies specific for TSPY useful in the prostate cancer diagnostic/prognostic and therapeutic methods described above, may be prepared using standard technologies widely used in the art.
- antibodies may be prepared by immunizing a suitable mammalian host using a TSPY protein, peptide, or fragment, in isolated or immunoconjugated form (Antibodies: A Laboratory Manual, CSH Press, Eds., Harlow, and Lane (1988); Harlow, Antibodies, Cold Spring Harbor Press, NY (1989)).
- fusion proteins of TSPY may also be used, such as a TSPY GST-fusion protein (see Examples).
- a GST fusion protein comprising one or more of the extracellular loops of the TSPY protein may be produced and used as an immunogen to generate appropriate extracellular-reactive TSPY antibodies.
- a TSPY peptide may be synthesized and used as an immunogen.
- Cells expressing or overexpressing TSPY may also be used for immunizations.
- any cell engineered to express TSPY may be used. Such strategies may result in the production of monoclonal antibodies with enhanced capacities for recognizing endogenous TSPY.
- naked DNA immunization techniques known in the art may be used (with or without purified TSPY protein or TSPY expressing cells) to generate an immune response to the encoded immunogen (for review, see Donnelly et al., 1997, Ann. Rev. Immunol. 15: 617-648).
- the amino acid sequence of TSPY as shown in FIG. 1 may be used to select specific regions of the TSPY protein for generating antibodies.
- hydrophobicity and hydrophilicity analyses of the TSPY amino acid sequence may be used to identify hydrophilic regions in the TSPY structure.
- Regions of the TSPY protein that show immunogenic structure, as well as other regions and domains, can readily be identified using various other methods known in the art, such as Chou-Fasman, Garnier-Robson, Kyte-Doolittle, Eisenberg, Karplus-Schultz or Jameson-Wolf analysis. Methods for the generation of TSPY antibodies are further illustrated by way of the examples provided herein.
- TSPY immunogen is conducted generally by injection over a suitable time period and with use of a suitable adjuvant, as is generally understood in the art. During the immunization schedule, titers of antibodies can be taken to determine adequacy of antibody formation.
- TSPY monoclonal antibodies are preferred and may be produced by various means well known in the art.
- immortalized cell lines which secrete a desired monoclonal antibody may be prepared using the standard hybridoma technology of Kohler and Milstein or modifications which immortalize producing B cells, as is generally known.
- the immortalized cell lines secreting the desired antibodies are screened by immunoassay in which the antigen is the TSPY protein or a TSPY fragment.
- the cells may be expanded and antibodies produced either from in vitro cultures or from ascites fluid.
- TSPY polypeptides may be used as immunogens for generating monoclonal antibodies using traditional methods.
- a particular embodiment comprises an antibody which immunohistochemically stains cells transfected with an expression plasmid carrying the TSPY coding sequence, wherein the transfected cells express TSPY protein, but which does not immunohistochemically stain untransfected cells.
- Any mammalian cell line which is capable of expressing the TSPY protein on the cell surface is suitable, such as 293T cells.
- TSPY monoclonal antibodies may be generated using NIH 3T3 cells expressing TSPY as an immunogen to generate mAbs that recognize the cell surface epitopes of TSPY.
- Reactive mAbs may be screened by cell-based ELISAs using PC-3 cells over-expressing TSPY.
- recombinant TSPY protein generated with an amino-terminal His-tag using a suitable expression system e.g., baculovirus expression system pBlueBac4.5, Invitrogen
- a suitable expression system e.g., baculovirus expression system pBlueBac4.5, Invitrogen
- the antibodies or fragments may also be produced, using current technology, by recombinant means. Regions that bind specifically to the desired regions of the TSPY protein can also be produced in the context of chimeric or CDR grafted antibodies of multiple species origin. Humanized or human TSPY antibodies may also be produced and are preferred for use in therapeutic contexts. Methods for humanizing murine and other non-human antibodies by substituting one or more of the non-human antibody CDRs for corresponding human antibody sequences are well known (see for example, Jones et al., 1986, Nature 321 : 522-525; Riechmnan et al., 1988, Nature 332: 323-327; Verhoeyen et al., 1988, Science 239: 1534-1536).
- Fully human TSPY monoclonal antibodies may be generated using cloning technologies employing large human Ig gene combinatorial libraries (i.e., phage display) (Griffiths and Hoogenboom, Building an in vitro immune system: human antibodies from phage display libraries. In: Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man.
- Fully human TSPY monoclonal antibodies may also be produced using transgenic mice engineered to contain human immunoglobulin gene loci as described in PCT Patent Application W098/24893, Kucherlapati and Jakobovits et al., published December 3, 1997 (see also, Jakobovits, 1998, Exp. Opin. Invest. Drugs 7(4): 607-614). This method avoids the in vitro manipulation required with phage display technology and efficiently produces high affinity authentic human antibodies.
- Reactivity of TSPY antibodies with a TSPY protein may be established by a number of well known means, including Western blot, immunoprecipitation, ELISA, and FACS analyses using, as appropriate, TSPY proteins, peptides, TSPY-expressing cells or extracts thereof.
- a TSPY antibody or fragment thereof of the invention may be labeled with a detectable marker or conjugated to a second molecule, such as a cytotoxic agent, and used for targeting the second molecule to a TSPY positive cell (Vitetta, E.S. et al., 1993,
- Suitable detectable markers include, but are not limited to, a radioisotope, a fluorescent compound, a bioluminescent compound, chemiluminescent compound, a metal chelator or an enzyme.
- a radioisotope a fluorescent compound
- a bioluminescent compound a bioluminescent compound
- chemiluminescent compound a metal chelator or an enzyme.
- bi-specific antibodies specific for two or more TSPY epitopes may be generated using methods generally known in the art.
- Homodimeric antibodies may also be generated by cross-linking techniques known in the art (e.g., Wolff et al., Cancer Res.
- LAPC xenografts were obtained from Dr. Charles Sawyers (UCLA) and generated as described (Klein et al, 1997, Nature Med. 3: 402-408). Androgen dependent and independent LAPC-4 xenografts LAPC-4 AD and Al, respectively) and LAPC-9 AD xenografts were grown in male SCID mice and were passaged as small tissue chunks in recipient males.
- LAPC-4 Al xenografts were derived from LAPC-4 AD tumors. Male mice bearing LAPC-4 AD tumors were castrated and maintained for 2-3 months. After the LAPC-4 tumors re-grew, the tumors were harvested and passaged in castrated males or in female SCID mice.
- Human cell lines e.g., HeLa
- HeLa Human cell lines
- DMEM fetal calf serum
- Tumor tissue and cell lines were homogenized in Trizol reagent (Life Technologies, Gibco BRL) using 10 ml/ g tissue or 10 ml/ 10 8 cells to isolate total RNA.
- Poly A RNA was purified from total RNA using Qiagen's Oligotex mRNA Mini and Midi kits. Total and mRNA were quantified by spectrophotometric analysis (O.D. 260/280 nm) and analyzed by gel electrophoresis.
- Nested primer (NP)1 5'TCGAGCGGCCGCCCGGGCAGGA3'
- Nested primer (NP)2 5 ⁇ GCGTGGTCGCGGCCGAGGA3' Suppression Subtractive Hybridization:
- SSH Suppression Subtractive Hybridization
- Double stranded cDNAs corresponding to tester and driver cDNAs were synthesized from 2 ⁇ g of poly(A) + RNA isolated from the relevant xenograft tissue, as described above, using CLONTECH's PCR-Select cDNA Subtraction Kit and 1 ng of oligonucleotide DPNCDN as primer. First- and second-strand synthesis were carried out as described in the Kit's user manual protocol (CLONTECH Protocol No. PT1117-1 , Catalog No. K1804-1). The resulting cDNA was digested with Dpn II for 3 hrs. at 37°C. Digested cDNA was extracted with phenol/chloroform (1 :1) and ethanol precipitated.
- Driver cDNA was generated by combining in a 1 :1 ratio Dpn II digested cDNA from the relevant xenograft source (see above) with a mix of digested cDNAs derived from human benign prostatic hyperplasia (BPH), the human cell lines HeLa, 293, A431 , Colo205, and mouse liver.
- BPH human benign prostatic hyperplasia
- Tester cDNA was generated by diluting 1 ⁇ l of Dpn II digested cDNA from the relevant xenograft source (see above) (400 ng) in 5 ⁇ l of water. The diluted cDNA (2 ⁇ l, 160 ng) was then ligated to 2 ⁇ l of Adaptor 1 and Adaptor 2 (10 ⁇ M), in separate ligation reactions, in a total volume of 10 ⁇ l at 16°C overnight, using 400 u of T4 DNA ligase (CLONTECH). Ligation was terminated with 1 ⁇ l of 0.2 M EDTA and heating at 72°C for 5 min.
- the first hybridization was performed by adding 1.5 ⁇ l (600 ng) of driver cDNA to each of two tubes containing 1.5 ⁇ l (20 ng) Adaptor 1- and Adaptor 2- ligated tester cDNA. In a final volume of 4 ⁇ l, the samples were overlaid with mineral oil, denatured in an MJ Research thermal cycler at 98°C for 1.5 minutes, and then were allowed to hybridize for 8 hrs at 68 C C. The two hybridizations were then mixed together with an additional 1 ⁇ l of fresh denatured driver cDNA and were allowed to hybridize overnight at 68°C. The second hybridization was then diluted in 200 ⁇ l of 20 mM Hepes, pH 8.3, 50 mM NaCI, 0.2 mM EDTA, heated at 70°C for 7 min. and stored at -20°C.
- PCR Amplification Cloning and Sequencing of Gene Fragments Generated from SSH: To amplify gene fragments resulting from SSH reactions, two PCR amplifications were performed. In the primary PCR reaction 1 ⁇ l of the diluted final hybridization mix was added to 1 ⁇ l of PCR primer 1 (10 ⁇ M), 0.5 ⁇ l dNTP mix (10 ⁇ M), 2.5 ⁇ l 10 x reaction buffer (CLONTECH) and 0.5 ⁇ l 50 x Advantage cDNA polymerase Mix (CLONTECH) in a final volume of 25 ⁇ l.
- PCR 1 was conducted using the following conditions: 75°C for 5 min., 94°C for 25 sec, then 27 cycles of 94°C for 10 sec, 66°C for 30 sec, 72°C for 1.5 min. Five separate primary PCR reactions were performed for each experiment. The products were pooled and diluted 1 :10 with water. For the secondary PCR reaction, 1 ⁇ l from the pooled and diluted primary PCR reaction was added to the same reaction mix as used for PCR 1 , except that primers NP1 and NP2 (10 ⁇ M) were used instead of PCR primer 1.
- PCR 2 was performed using 10-12 cycles of 94°C for 10 sec, 68°C for 30 sec, 72°C for 1.5 minutes. The PCR products were analyzed using 2% agarose gel electrophoresis.
- PCR products were inserted into pCR2.1 using the T/A vector cloning kit (Invitrogen). Transformed E. coli were subjected to blue/white and ampicillin selection. White colonies were picked and arrayed into 96 well plates and were grown in liquid culture overnight. To identify inserts, PCR amplification was performed on 1 ml of bacterial culture using the conditions of PCR1 and NP1 and NP2 as primers. PCR products were analyzed using 2% agarose gel electrophoresis.
- Bacterial clones were stored in 20% glycerol in a 96 well format. Plasmid DNA was prepared, sequenced, and subjected to nucleic acid homology searches of the GenBank, dBest, and NCI-CGAP databases.
- First strand cDNAs were generated from 1 ⁇ g of mRNA with oligo (dT)12-18 priming using the Gibco-BRL Superscript Preamplification system. The manufacturers protocol was used and included an incubation for 50 min at 42°C with reverse transcriptase followed by RNAse H treatment at 37°C for 20 min. After completing the reaction, the volume was increased to 200 ⁇ l with water prior to normalization. First strand cDNAs from 16 different normal human tissues were obtained from Clontech.
- First strand cDNA (5 ⁇ l) was amplified in a total volume of 50 ⁇ l containing 0.4 ⁇ M primers, 0.2 ⁇ M each dNTPs, 1XPCR buffer (Clontech, 10 mM Tris-HCL, 1.5 mM MgCI 2 , 50 mM KCI, pH8.3) and 1X Klentaq DNA polymerase (Clontech).
- PCR Five ⁇ l of the PCR reaction was removed at 18, 20, and 22 cycles and used for agarose gel electrophoresis.
- PCR was performed using an MJ Research thermal cycler under the following conditions: initial denaturation was at 94°C for 15 sec, followed by a 18, 20, and 22 cycles of 94°C for 15, 65°C for 2 min, 72°C for 5 sec. A final extension at 72°C was carried out for 2 min.
- the band intensities of the 283 bp ⁇ -actin bands from multiple tissues were compared by visual inspection. Dilution factors for the first strand cDNAs were calculated to result in equal ⁇ -actin band intensities in all tissues after 22 cycles of PCR. Three rounds of normalization were required to achieve equal band intensities in all tissues after 22 cycles of PCR.
- SSH clones candidate gene fragment clones
- All candidate clones were sequenced and subjected to homology analysis against all sequences in the major public gene and EST databases in order to provide information on the identity of the corresponding gene and to help guide the decision to analyze a particular gene for differential expression.
- One of the SHH clones comprising about 107 bp, showed identity to the human Y- specific gene TSPY (testis-specific protein Y-encoded) (Arnemann, J et al., 1991 , Genomics 11 : 108-114).
- the nucleotide sequence of this SHH clone is shown in FIG. 2.
- Differential expression analysis by RT-PCR showed over-expression in all LAPC xenografts relative to normal prostate tissue, with the highest levels observed in the LAPC-4 xenografts (FIG. 3, Panel A).
- RT-PCR expression analysis of first strand cDNAs from 16 normal tissues detected expression only in testis after 30 cycles of PCR amplification (FIG. 3, panels B and C). After 35 cycles of amplification, the only other tissue in which expression of TSPY was detected was prostate, but only at significantly lower levels in relation to expression in testis (FIG. 3, Panels B and C).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU65024/99A AU6502499A (en) | 1998-10-02 | 1999-10-02 | Methods and compositions for the diagnosis and therapy of prostate cancer |
CA002344563A CA2344563A1 (en) | 1998-10-02 | 1999-10-02 | Methods and compositions for the diagnosis and therapy of prostate cancer |
IL14231199A IL142311A0 (en) | 1998-10-02 | 1999-10-02 | Methods and compositions for the diagnosis and therapy of prostate cancer |
EP99952982A EP1117837A2 (en) | 1998-10-02 | 1999-10-02 | Methods and compositions for the diagnosis and therapy of prostate cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10289398P | 1998-10-02 | 1998-10-02 | |
US60/102,893 | 1998-10-02 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2000020638A2 WO2000020638A2 (en) | 2000-04-13 |
WO2000020638A9 true WO2000020638A9 (en) | 2000-10-05 |
WO2000020638A3 WO2000020638A3 (en) | 2000-11-09 |
Family
ID=22292250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/022575 WO2000020638A2 (en) | 1998-10-02 | 1999-10-02 | Methods and compositions for the diagnosis and therapy of prostate cancer |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1117837A2 (en) |
AU (1) | AU6502499A (en) |
CA (1) | CA2344563A1 (en) |
IL (1) | IL142311A0 (en) |
WO (1) | WO2000020638A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2480811A1 (en) * | 2002-04-01 | 2003-10-16 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL141444A0 (en) * | 1998-08-31 | 2002-03-10 | Urogenesys Inc | Phelix: a testis specific protein expressed in cancer |
-
1999
- 1999-10-02 AU AU65024/99A patent/AU6502499A/en not_active Abandoned
- 1999-10-02 CA CA002344563A patent/CA2344563A1/en not_active Abandoned
- 1999-10-02 IL IL14231199A patent/IL142311A0/en unknown
- 1999-10-02 WO PCT/US1999/022575 patent/WO2000020638A2/en not_active Application Discontinuation
- 1999-10-02 EP EP99952982A patent/EP1117837A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU6502499A (en) | 2000-04-26 |
CA2344563A1 (en) | 2000-04-13 |
WO2000020638A2 (en) | 2000-04-13 |
EP1117837A2 (en) | 2001-07-25 |
WO2000020638A3 (en) | 2000-11-09 |
IL142311A0 (en) | 2002-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7968283B2 (en) | Gene expressed in prostate cancer | |
US8003758B2 (en) | BPC-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells | |
CA2329137C (en) | Novel tumor antigen useful in diagnosis and therapy of prostrate and colon cancer | |
US7008779B1 (en) | PHELIX: a testis-specific protein expressed in cancer | |
US6652859B1 (en) | PTANS: testis specific proteins expressed in prostate cancer | |
WO2000020638A9 (en) | Methods and compositions for the diagnosis and therapy of prostate cancer | |
AU2006225260B2 (en) | Gene expressed in prostate cancer | |
AU1097500A (en) | Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6 | |
AU2006201736A1 (en) | BPC-1: a secreted brain specific protein expressed and secreted by prostate and bladder cancer cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 1999 65024 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AT AT AU BR CA CH CN DE DE DK DK ES FI FI GB IL JP KR MX NO NZ RU SE SG US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AT AT AU BR CA CH CN DE DE DK DK ES FI FI GB IL JP KR MX NO NZ RU SE SG US |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/4-4/4, DRAWINGS, REPLACED BY NEW PAGES 1/4-4/4; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AT AT AU BR CA CH CN DE DE DK DK ES FI FI GB IL JP KR MX NO NZ RU SE SG US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
ENP | Entry into the national phase |
Ref document number: 2344563 Country of ref document: CA Ref country code: CA Ref document number: 2344563 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 65024/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999952982 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09806352 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999952982 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999952982 Country of ref document: EP |